Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2017-01-10 Regulatory Filings
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
105年12月背書保證與資金貸與
Regulatory Filings Classification · 90% confidence The document is very short (601 characters) and contains tabular financial data related to loan balances, endorsements, and guarantees for the company and its subsidiaries. It does not contain comprehensive financial statements or detailed analysis typical of annual or interim reports. There is no indication of a meeting, voting results, or management changes. The content is a regulatory disclosure of financial information related to guarantees and loans, which fits best under general regulatory announcements. Therefore, it is classified as a Regulatory Filing (RNS).
2017-01-10 Chinese
105年12月營業收入
Fund Information / Factsheet Classification · 85% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 景岳, with data for December of 民國105 (2016). It includes percentage changes compared to the previous year and explanatory notes about accounting standards (IFRS) and reporting practices. The document is very short (765 characters) and primarily presents summarized financial data without detailed financial statements or management discussion. It does not appear to be a full annual or interim report, nor an earnings release or investor presentation. It is more of a brief financial summary or factsheet. Given the concise nature and summary format, the best fitting category is Fund Information / Factsheet (FS).
2017-01-10 Chinese
公告本公司申請股票上櫃轉上市時所出具之承諾事項 暨其後續執行情形
Regulatory Filings Classification · 95% confidence The document is a short announcement (770 characters) from a listed company (景岳生物科技股份有限公司) regarding the company's commitments made at the time of applying for stock listing transfer and the subsequent execution status. It references compliance with a Taiwan Stock Exchange regulation and reports on the status as of a certain date. The document does not contain financial statements or detailed financial data but rather a compliance update related to listing commitments. It is not a full financial report, audit report, or earnings release. It is also not a report publication announcement since it contains substantive content about the company's commitments and execution status. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2017-01-09 Chinese
公告本公司有價證券有異常交易情形,故公布基本資料及 相關財務業務等重大訊息
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (3164 景岳) disclosing abnormal trading activity of its securities and providing related financial information such as revenue, pre-tax profit, post-tax profit, and earnings per share for recent periods. It references instructions from the Taiwan Stock Exchange and includes financial data comparisons but does not contain a full financial report or detailed analysis. The document length is only 1292 characters, which is quite short and consistent with a regulatory announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. The content fits the profile of a Regulatory Filing (RNS) as it is a compliance disclosure about abnormal trading and financial status without being a full report or presentation.
2016-12-29 Chinese
105年12月法人說明會簡報 — 316420161221E001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation or brochure about GenMont Biotech Incorporation, focusing on company history, product introductions, clinical trials, patents, and scientific publications. It contains no financial statements, no regulatory filing references, no voting results, no management or board changes, no earnings announcements, no legal proceedings, no capital or financing updates, and no merger or acquisition information. The content is primarily promotional and informational about products and R&D achievements, not a formal financial or regulatory report. The document length is about 15,000 characters, but it is not a report itself; it is more akin to an investor or corporate presentation. Therefore, the best fitting category is Investor Presentation (IP).
2016-12-21 Chinese
105年12月法人說明會簡報 — 316420161221M001.pdf
Regulatory Filings Classification · 85% confidence The document is a detailed corporate presentation or brochure about GenMont Biotech Incorporation, focusing on its history, product lines, patents, clinical trials, and scientific publications. It contains no financial statements, no regulatory or legal announcements, no management or board changes, no earnings or capital updates, and no voting or governance materials. The content is promotional and informational about the company's products and R&D achievements rather than a formal financial or regulatory filing. The length is about 15,000 characters, but the content is descriptive and marketing-oriented, not a report or announcement of a report. Therefore, it does not fit into categories like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Regulatory Filings (RNS). It is not a presentation for investors (IP) in the typical sense of financial or strategic presentation but rather a corporate product and R&D overview. Given the available categories, the best fit is Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not neatly fit into other categories, since this is a corporate informational document without financial or regulatory filing characteristics.
2016-12-21 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.